Literature DB >> 18025475

Tumor immune escape by the loss of homeostatic chemokine expression.

Andor Pivarcsi1, Anja Müller, Andreas Hippe, Juliane Rieker, Anke van Lierop, Martin Steinhoff, Stephan Seeliger, Robert Kubitza, Ulrich Pippirs, Stephan Meller, Peter A Gerber, Ruediger Liersch, Erich Buenemann, Eniko Sonkoly, Ulrike Wiesner, Thomas K Hoffmann, Leonid Schneider, Roland Piekorz, Elaine Enderlein, Julia Reifenberger, Ulrich-Peter Rohr, Rainer Haas, Petra Boukamp, Ingo Haase, Bernd Nürnberg, Thomas Ruzicka, Albert Zlotnik, Bernhard Homey.   

Abstract

The novel keratinocyte-specific chemokine CCL27 plays a critical role in the organization of skin-associated immune responses by regulating T cell homing under homeostatic and inflammatory conditions. Here we demonstrate that human keratinocyte-derived skin tumors may evade T cell-mediated antitumor immune responses by down-regulating the expression of CCL27 through the activation of epidermal growth factor receptor (EGFR)-Ras-MAPK-signaling pathways. Compared with healthy skin, CCL27 mRNA and protein expression was progressively lost in transformed keratinocytes of actinic keratoses and basal and squamous cell carcinomas. In vivo, precancerous skin lesions as well as cutaneous carcinomas showed significantly elevated levels of phosphorylated ERK compared with normal skin, suggesting the activation of EGFR-Ras signaling pathways in keratinocyte-derived malignancies. In vitro, exogenous stimulation of the EGFR-Ras signaling pathway through EGF or transfection of the dominant-active form of the Ras oncogene (H-RasV12) suppressed whereas an EGFR tyrosine kinase inhibitor increased CCL27 mRNA and protein production in keratinocytes. In mice, neutralization of CCL27 led to decreased leukocyte recruitment to cutaneous tumor sites and significantly enhanced primary tumor growth. Collectively, our data identify a mechanism of skin tumors to evade host antitumor immune responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18025475      PMCID: PMC2141907          DOI: 10.1073/pnas.0705673104

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

Review 1.  The biology of chemokines and their receptors.

Authors:  D Rossi; A Zlotnik
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 2.  Immunotherapy for nonmelanoma skin cancer: does it have a future?

Authors:  Mirjana Urosevic; Reinhard Dummer
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

3.  CCL27-CCR10 interactions regulate T cell-mediated skin inflammation.

Authors:  Bernhard Homey; Harri Alenius; Anja Müller; Hortensia Soto; Edward P Bowman; Wei Yuan; Leslie McEvoy; Antti I Lauerma; Till Assmann; Erich Bünemann; Maili Lehto; Henrik Wolff; David Yen; Heather Marxhausen; Wayne To; Jonathon Sedgwick; Thomas Ruzicka; Percy Lehmann; Albert Zlotnik
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

Review 4.  Chemokines: agents for the immunotherapy of cancer?

Authors:  Bernhard Homey; Anja Müller; Albert Zlotnik
Journal:  Nat Rev Immunol       Date:  2002-03       Impact factor: 53.106

5.  CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells.

Authors:  J Morales; B Homey; A P Vicari; S Hudak; E Oldham; J Hedrick; R Orozco; N G Copeland; N A Jenkins; L M McEvoy; A Zlotnik
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-07       Impact factor: 11.205

6.  Cutting edge: the orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC).

Authors:  B Homey; W Wang; H Soto; M E Buchanan; A Wiesenborn; D Catron; A Müller; T K McClanahan; M C Dieu-Nosjean; R Orozco; T Ruzicka; P Lehmann; E Oldham; A Zlotnik
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

7.  Tumor progression of skin carcinoma cells in vivo promoted by clonal selection, mutagenesis, and autocrine growth regulation by granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor.

Authors:  M M Mueller; W Peter; M Mappes; A Huelsen; H Steinbauer; P Boukamp; M Vaccariello; J Garlick; N E Fusenig
Journal:  Am J Pathol       Date:  2001-10       Impact factor: 4.307

8.  Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector.

Authors:  N Okada; A Sasaki; M Niwa; Y Okada; Y Hatanaka; Y Tani; H Mizuguchi; S Nakagawa; T Fujita; A Yamamoto
Journal:  Cancer Gene Ther       Date:  2006-04       Impact factor: 5.987

9.  Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.

Authors:  A Kumar; D R Soprano; H K Parekh
Journal:  Cancer Res       Date:  2001-10-15       Impact factor: 12.701

10.  Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment.

Authors:  E Stockfleth; C Ulrich; T Meyer; E Christophers
Journal:  Recent Results Cancer Res       Date:  2002
View more
  56 in total

Review 1.  Rosacea: The cytokine and chemokine network.

Authors:  Peter Arne Gerber; Bettina Alexandra Buhren; Martin Steinhoff; Bernhard Homey
Journal:  J Investig Dermatol Symp Proc       Date:  2011-12

Review 2.  CCR10 and its ligands in regulation of epithelial immunity and diseases.

Authors:  Na Xiong; Yaoyao Fu; Shaomin Hu; Mingcan Xia; Jie Yang
Journal:  Protein Cell       Date:  2012-06-08       Impact factor: 14.870

3.  EGFR inhibitors, MHC expression and immune responses : Can EGFR inhibitors be used as immune response modifiers?

Authors:  Brian P Pollack
Journal:  Oncoimmunology       Date:  2012-01-01       Impact factor: 8.110

Review 4.  Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity.

Authors:  Sara Pilotto; Miguel Angel Molina-Vila; Niki Karachaliou; Luisa Carbognin; Santiago Viteri; Maria González-Cao; Emilio Bria; Giampaolo Tortora; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2015-12

5.  Invasion and metastasis: stem cells, screens and survival. Conference on Invasion and Metastasis.

Authors:  Nicolas Tapon; Ulrike Ziebold
Journal:  EMBO Rep       Date:  2008-10-10       Impact factor: 8.807

6.  Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.

Authors:  Q Jiao; C Liu; W Li; W Li; F Fang; Q Qian; X Zhang
Journal:  Clin Exp Immunol       Date:  2017-03-12       Impact factor: 4.330

Review 7.  Immunological hallmarks of stromal cells in the tumour microenvironment.

Authors:  Shannon J Turley; Viviana Cremasco; Jillian L Astarita
Journal:  Nat Rev Immunol       Date:  2015-10-16       Impact factor: 53.106

8.  PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations.

Authors:  Mei Ji; Yan Liu; Qing Li; Xiaodong Li; Zhonghua Ning; Weiqing Zhao; Hongbing Shi; Jingting Jiang; Changping Wu
Journal:  Cancer Biol Ther       Date:  2016-03-08       Impact factor: 4.742

Review 9.  Homeostatic chemokine receptors and organ-specific metastasis.

Authors:  Albert Zlotnik; Amanda M Burkhardt; Bernhard Homey
Journal:  Nat Rev Immunol       Date:  2011-08-25       Impact factor: 53.106

10.  Dynamic interplay of oncogenes and T cells induces PD-L1 in the tumor microenvironment.

Authors:  Andrew J Rech; Robert H Vonderheide
Journal:  Cancer Discov       Date:  2013-12       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.